Why the study?
Real-world data on GDMT use, dose, and prognostic implications in patients with advanced HFrEF are lacking.
Does guideline-directed medical therapy (BB, ACEi/ARB/ARNI) reduce death or heart failure hospitalizations in patients with severe HFrEF?
Does guideline-directed medical therapy (BB, ACEi/ARB/ARNI) reduce death or heart failure hospitalizations in patients with severe HFrEF?
In patients with severe HFrEF, GDMT prescription and uptitration remain limited, often due to clinical inertia, despite BB and ACEi/ARB/ARNI being associated with significantly lower mortality and morbidity.
No takes yet. Share an insight, caveat, or question.
May support GDMT consideration in severe HFrEF; leaves open randomized confirmation before practice change.
Tomasoni et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: